富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床研究

发布时间：2019-01-14 14:16

【摘要】：目的观察富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床疗效及安全性。方法将70例精神分裂症患者随机分为对照组35例和试验组35例。对照组予以阿立哌唑,初始剂量5 mg·d~(-1),bid,口服;根据病情1周内逐渐增加至20~30 mg·d~(-1),bid。试验组予以阿立哌唑5~10 mg·d~(-1),bid,口服+富马酸喹硫平,最初剂量为100 mg·d~(-1),bid,口服;根据病情逐渐增加,在1周内将富马酸喹硫平的剂量调整为400~600 mg·d~(-1),bid;治疗1个月后,根据患者具体病情将富马酸喹硫平的剂量增加至800 mg·d~(-1),bid。2组患者均治疗2个月。比较2组患者的临床疗效、简明精神疾病评定量表(BPRS)评分、匹兹堡睡眠质量指数(PSQI)、阳性与与阴性症状量表(PANSS)评分,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为88.57%(31/35例)和85.71%(30/35例),差异无统计学意义(P0.05)。治疗后,试验组与对照组的BPRS总分分别为(34.57±2.67),(41.95±1.64)分;PSQI总分分别为(6.49±0.19),(13.05±0.97)分,差异均有统计学意义(均P0.05)。治疗后,试验组与对照组的阳性症状评分分别为(15.66±1.21),(15.52±1.32)分;阴性症状分别为(14.84±1.63),(15.13±1.10)分;病理症状分别为(31.37±2.19),(31.32±2.19)分;PANSS总分分别为(66.56±2.34),(66.10±2.37)分,差异均无统计学意义(均P0.05)。试验组发生的药物不良反应主要有恶心呕吐、心动过速、静坐不能、震颤;对照组发生的药物不良反应主要有失眠症状、心动过速、肌强直、静坐不能、流涎。试验组和对照组的药物不良反应发生率分别为17.14%和45.71%,差异有统计学意义(P0.05)。结论富马酸喹硫平片联合阿立哌唑片与单用阿立哌唑片治疗精神分裂症的临床疗效相当,但前者可显著改善患者的病情和睡眠质量,且安全性较高。
[Abstract]:Objective to observe the efficacy and safety of quintiapine fumarate tablets combined with aripiprazole tablets in the treatment of schizophrenia. Methods 70 patients with schizophrenia were randomly divided into control group (n = 35) and experimental group (n = 35). The control group was given aripiprazole at an initial dose of 5 mg D1), bid, and gradually increased to 2030 mg D1), bid. within 1 week according to the condition of the disease. In the experimental group, aripiprazole was given orally for 10 mg D1), bid, and the initial dose was 100 mg D1), bid,. According to the gradual increase of the disease, the dose of quinolipine fumarate was adjusted to 400 ~ (-1) mg / d ~ (-1), bid; within one week. After one month of treatment, the dosage of quetiapine fumarate was increased to 800 mg D1 according to the specific condition of the patients. The patients in the bid.2 group were treated for 2 months. The clinical efficacy, (BPRS) score of brief psychiatric rating scale, (PANSS) score of Pittsburgh Sleep quality Index (PSQI),) positive and negative symptom scale, and the incidence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 88.57% (31 / 35 cases) and 85.71% (30 / 35 cases), respectively. The difference was not statistically significant (P0.05). After treatment, the total scores of BPRS and PSQI were (34.57 卤2.67), (, 41.95 卤1.64) and (6.49 卤0.19), (, 13.05 卤0.97) in the experimental group and the control group, respectively (P0.05). After treatment, the scores of positive symptoms and negative symptoms were (15.66 卤1.21), (卤1.32), (14.84 卤1.63), () and (15.13 卤1.10), respectively. The pathological symptoms were (31.37 卤2.19), (, 31.32 卤2.19), the total score of PANSS were (66.56 卤2.34), (, 66.10 卤2.37), the differences were not statistically significant (P0.05). The main adverse drug reactions in the test group were nausea and vomiting, tachycardia, sit-down and tremor, while the adverse drug reactions in the control group were mainly insomnia, tachycardia, myotonia, sedentary inability, salivation. The incidence of adverse drug reactions in test group and control group was 17.14% and 45.71% respectively, the difference was statistically significant (P0.05). Conclusion the clinical efficacy of quintiapine fumarate combined with aripiprazole in the treatment of schizophrenia is similar to that of aripiprazole alone, but the former can significantly improve the patient's condition and sleep quality, and the safety of the former is higher than that of aripiprazole alone.
【作者单位】：宁波市强制医疗所精神科;杭州市第七人民医院精神科;
【基金】：浙江省医药卫生科技计划基金资助项目(2015KYB303)
【分类号】：R749.3

【相似文献】